198 related articles for article (PubMed ID: 33117698)
1. Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy.
Ocáriz-Díez M; Cruellas M; Gascón M; Lastra R; Martínez-Lostao L; Ramírez-Labrada A; Paño JR; Sesma A; Torres I; Yubero A; Pardo J; Isla D; Gálvez EM
Front Oncol; 2020; 10():568939. PubMed ID: 33117698
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers of Immunotherapy Response in Patients with Non-Small-Cell Lung Cancer: Microbiota Composition, Short-Chain Fatty Acids, and Intestinal Permeability.
Moratiel-Pellitero A; Zapata-García M; Gascón-Ruiz M; Sesma A; Quílez E; Ramirez-Labrada A; Martínez-Lostao L; Domingo MP; Esteban P; Yubero A; Barbero-Herranz R; Moreno-Blanco A; Paño JR; Lastra R; Pardo J; Isla D; Del Campo R; Gálvez E
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539479
[TBL] [Abstract][Full Text] [Related]
3. The cancer microbiome.
Elinav E; Garrett WS; Trinchieri G; Wargo J
Nat Rev Cancer; 2019 Jul; 19(7):371-376. PubMed ID: 31186547
[TBL] [Abstract][Full Text] [Related]
4. Broadening oncological boundaries: the intratumoral microbiota.
Lu YQ; Qiao H; Tan XR; Liu N
Trends Microbiol; 2024 Feb; ():. PubMed ID: 38310023
[TBL] [Abstract][Full Text] [Related]
5. Unexpected guests in the tumor microenvironment: microbiome in cancer.
Wong-Rolle A; Wei HK; Zhao C; Jin C
Protein Cell; 2021 May; 12(5):426-435. PubMed ID: 33296049
[TBL] [Abstract][Full Text] [Related]
6. Microbiome dysbiosis in lung cancer: from composition to therapy.
Liu NN; Ma Q; Ge Y; Yi CX; Wei LQ; Tan JC; Chu Q; Li JQ; Zhang P; Wang H
NPJ Precis Oncol; 2020 Dec; 4(1):33. PubMed ID: 33303906
[TBL] [Abstract][Full Text] [Related]
7. How Could Antibiotics, Probiotics, and Corticoids Modify Microbiota and Its Influence in Cancer Immune Checkpoint Inhibitors: A Review.
Cruellas M; Yubero A; Zapata M; Galvez EM; Gascón M; Isla D; Lastra R; Martínez-Lostao L; Ocariz M; Pardo J; Ramírez A; Sesma A; Torres-Ramón I; Paño JR
Infect Immun; 2021 Aug; 89(9):e0066520. PubMed ID: 33526567
[TBL] [Abstract][Full Text] [Related]
8. The Lung Microbiome: A Central Mediator of Host Inflammation and Metabolism in Lung Cancer Patients?
Weinberg F; Dickson RP; Nagrath D; Ramnath N
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33375062
[TBL] [Abstract][Full Text] [Related]
9. Infections and Immunotherapy in Lung Cancer: A Bad Relationship?
Belluomini L; Caldart A; Avancini A; Dodi A; Trestini I; Kadrija D; Sposito M; Tregnago D; Casali M; Riva ST; Sartori G; Menis J; Milella M; Pilotto S
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375194
[TBL] [Abstract][Full Text] [Related]
10. The Resistance Mechanisms of Lung Cancer Immunotherapy.
Wang F; Wang S; Zhou Q
Front Oncol; 2020; 10():568059. PubMed ID: 33194652
[TBL] [Abstract][Full Text] [Related]
11. The association between proton pump inhibitors use and clinical outcome of patients receiving immune checkpoint inhibitors therapy.
Li M; Zeng C; Yao J; Ge Y; An G
Int Immunopharmacol; 2020 Nov; 88():106972. PubMed ID: 33182025
[TBL] [Abstract][Full Text] [Related]
12. The effect of intestinal flora on immune checkpoint inhibitors in tumor treatment: a narrative review.
Wang D; Hao H; Li X; Wang Z
Ann Transl Med; 2020 Sep; 8(17):1097. PubMed ID: 33145316
[TBL] [Abstract][Full Text] [Related]
13. Network Analysis of Gut Microbiome and Metabolome to Discover Microbiota-Linked Biomarkers in Patients Affected by Non-Small Cell Lung Cancer.
Vernocchi P; Gili T; Conte F; Del Chierico F; Conta G; Miccheli A; Botticelli A; Paci P; Caldarelli G; Nuti M; Marchetti P; Putignani L
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33227982
[TBL] [Abstract][Full Text] [Related]
14. The gut microbiome can be used to predict the gastrointestinal response and efficacy of lung cancer patients undergoing chemotherapy.
Zhang M; Zhou H; Xu S; Liu D; Cheng Y; Gao B; Li X; Chen J
Ann Palliat Med; 2020 Nov; 9(6):4211-4227. PubMed ID: 33302682
[TBL] [Abstract][Full Text] [Related]
15. Physiologic colonic uptake of
Cvetkovic L; Régis C; Richard C; Derosa L; Leblond A; Malo J; Messaoudene M; Desilets A; Belkaid W; Elkrief A; Routy B; Juneau D
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1550-1559. PubMed ID: 33128571
[TBL] [Abstract][Full Text] [Related]
16. [Clinical characteristics and microbiome analysis in patients with anti-programmed cell death protein 1 related colitis].
Tan B; Tang H; Ren XY; Zhou WX; Qian JM; Zhang L; Zhang XT
Zhonghua Nei Ke Za Zhi; 2020 Nov; 59(11):887-893. PubMed ID: 33120493
[No Abstract] [Full Text] [Related]
17. Lower Airway Dysbiosis Affects Lung Cancer Progression.
Tsay JJ; Wu BG; Sulaiman I; Gershner K; Schluger R; Li Y; Yie TA; Meyn P; Olsen E; Perez L; Franca B; Carpenito J; Iizumi T; El-Ashmawy M; Badri M; Morton JT; Shen N; He L; Michaud G; Rafeq S; Bessich JL; Smith RL; Sauthoff H; Felner K; Pillai R; Zavitsanou AM; Koralov SB; Mezzano V; Loomis CA; Moreira AL; Moore W; Tsirigos A; Heguy A; Rom WN; Sterman DH; Pass HI; Clemente JC; Li H; Bonneau R; Wong KK; Papagiannakopoulos T; Segal LN
Cancer Discov; 2021 Feb; 11(2):293-307. PubMed ID: 33177060
[TBL] [Abstract][Full Text] [Related]
18. Microbiota Biomarkers for Lung Cancer.
Leng Q; Holden VK; Deepak J; Todd NW; Jiang F
Diagnostics (Basel); 2021 Feb; 11(3):. PubMed ID: 33673596
[TBL] [Abstract][Full Text] [Related]
19. Lower Airway Dysbiosis Exacerbates Lung Cancer.
Zitvogel L; Kroemer G
Cancer Discov; 2021 Feb; 11(2):224-226. PubMed ID: 33531424
[TBL] [Abstract][Full Text] [Related]
20. Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients.
Zhang C; Wang J; Sun Z; Cao Y; Mu Z; Ji X
Cancer Sci; 2021 Aug; 112(8):3005-3017. PubMed ID: 34028936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
